Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Pascal Benkert, Sandra Vukusic et al.|Journal of Neurology Neurosurgery & Psychiatry|2024Cited by 4
Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)—an individual participant data meta-analysisLisa G Schoof, Jeppe Romme Christensen, Brit Ellen Rød et al.|Multiple Sclerosis and Related Disorders|2025Cited by 3